secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-051876
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year
-------------------------------------------------------------------------

- Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.
- Net loss FY 2023 $67.0M ($1.48 per share) vs $24.5M ($0.72 per share) in FY 2022; non-GAAP net loss $51.8M ($1.14 per share).
- SG&A expenses surged to $47.3M for FY 2023 (FY 2022: $17.4M) driven by commercial ramp and stock compensation.
- Cash and equivalents $69.5M as of Dec 31, 2023; runway into Q2 2025.
- CMS issued permanent J-code for YCANTH (effective Apr 1, 2024); FDA aligned on Phase 3 design for common warts; VP-315 Phase 2 top-line data expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/0001193125-24-051876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/d795567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-051876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer